New Mexico Officials Set to Discuss Adding Female Orgasmic Disorder to Medical Marijuana Program Today
- New Mexico health officials are considering adding female orgasmic disorder as a qualifying condition for medical marijuana, potentially making it the third state to do so after Connecticut and Illinois.
- The Medical Cannabis Advisory Board will discuss the proposal and provide a public update; the board previously approved it in October 2024 with a 6-2 vote.
- Supporters cite research showing cannabis may improve orgasm frequency, ease, and satisfaction by reducing anxiety and improving physiological responses, addressing a condition affecting up to 72% of premenopausal women with limited traditional treatment options.
- The proposal reflects a broader shift toward recognizing women's health conditions in medical marijuana programs and will be further evaluated during a virtual public meeting scheduled from 1:30 p.m. to 4:30 p.m. Mountain Time.
New Mexico health officials are scheduled to discuss today a proposal that could make the state just the third in the nation to add female orgasmic disorder as a qualifying condition for medical marijuana.
The issue is on the agenda for the Medical Cannabis Advisory Board’s meeting Monday afternoon, where members are set to provide a public update on the petition. If the recommendation is ultimately adopted by the state’s health secretary, New Mexico would join Connecticut and Illinois in recognizing the condition under its medical marijuana program.
Supporters say the move would address a condition that affects a significant number of women but has received little attention from traditional medicine.
Suzanne Mulvehill, PhD, a clinical sexologist and orgasmologist, told The Marijuana Herald “Female orgasmic difficulty affects up to 72% of premenopausal women, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, text revision (DSM-5-TR), yet there are no FDA-approved pharmacological treatments and limited effective treatments. The Board’s recommendation was based on over 50 years of research, clinical experience, and patient testimony demonstrating that cannabis may improve orgasm frequency, ease, and satisfaction for women who experience orgasm difficulty.”
Backers of the proposal say marijuana may help by reducing anxiety, improving attentional focus and helping facilitate the physiological responses associated with orgasm. They also say the recommendation reflects a broader shift in how women’s health conditions are being considered within state medical marijuana programs.
The Medical Cannabis Advisory Board formally approved the petition in October 2024 by a 6 to 2 vote, recommending that female orgasmic disorder be added under the Lynn and Erin Compassionate Use Act. Monday’s agenda item is expected to provide an update on where the proposal stands as the regulatory process continues.
The public meeting is scheduled for 1:30 p.m. to 4:30 p.m. Mountain Time and will be held virtually.